Trials / Completed
CompletedNCT03402295
Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
Superiority of the Triple Combinations of Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in Patients With Newly Diagnose Multiple Myeloma, Eligible for Transplantation
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 311 (actual)
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study compared two main different induction protocols used to treat myeloma eligible patients in Brazil. VCD against CTD.
Detailed description
The primary aim was observe response rate after 4 induction cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib, cyclophosphamide, thalidomide, dexamethasone | Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida) |
Timeline
- Start date
- 2009-06-15
- Primary completion
- 2014-06-15
- Completion
- 2017-10-15
- First posted
- 2018-01-18
- Last updated
- 2018-01-18
Source: ClinicalTrials.gov record NCT03402295. Inclusion in this directory is not an endorsement.